Telix Pharmaceuticals LimitedASX: TLX

Telix and DuChemBio - South Korea Partnership

· Issued by Telix Pharmaceuticals Limited

Filed with ASX · · 2 pages · English

Melbourne (Australia) and Seoul (South Korea) – 3 December 2020. Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has entered into a commercialisation and partnership agreement with DuChemBio Co, Ltd. (DuChemBio), the leading South Korean 68 radiopharmaceutical company, for Telix’s prostate cancer imaging product TLX591-CDx ( Ga- PSMA-11). DuChemBio has the large

Telix Pharmaceuticals Limited on 6ix

In the deck

Earlier from Telix Pharmaceuticals

Later from Telix Pharmaceuticals

All Telix Pharmaceuticals news releases